Latest Breaking News On - Avidity partners - Page 10 : comparemela.com

Dianthus Therapeutics Announces Positive Top-line Phase 1 Data and Debuts Trading on Nasdaq as DNTH

Dianthus Therapeutics Announces Positive Top-line Phase 1 Data and Debuts Trading on Nasdaq as DNTH
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesMarino garciaSimrat randhawaDemyelinating polyneuropathyTellus bioventuresDianthus therapeutics incFidelity management research companyMyasthenia gravisMultifocal motor neuropathyChronic inflammatory demyelinating polyneuropathyNasdaq capital marketMagenta therapeuticsChief executive officerChief medical officerFidelity management

Dianthus Therapeutics Announces Positive Top-line Phase 1

Positive top-line Phase 1 data for lead clinical program DNTH103 confirm potent classical pathway inhibition, extended half-life, and a potentially.

New yorkUnited statesDemyelinating polyneuropathyTellus bioventuresSimrat randhawaMarino garciaDianthus therapeutics incFidelity management research companyMyasthenia gravisMultifocal motor neuropathyChronic inflammatory demyelinating polyneuropathyNasdaq capital marketMagenta therapeuticsChief executive officerChief medical officerFidelity management

Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics

Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Erin murphyNivi nehraAndrew mckibbenSam martinNaomi eichenbaumFrazier life sciencesEuropean commissionSecurities exchangeMirum pharmaceuticals incCorporate communicationsHealth canadaSofinnova investments incExchange commissionTravere therapeutics incTravere therapeuticsAsset purchase

AN2 Therapeutics Announces Pricing of $70 0 Million Underwritten Offering of Common Stock

AN2 Therapeutics Announces Pricing of $70 0 Million Underwritten Offering of Common Stock
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkMarshall waceAnne bowdidgeEvercore groupTherapeutics incSyndicate departmentFrazier life sciencesOppenheimer coCompany contactsLeerink partnersAdage capital partnersAvidity partnersJanus henderson investorsSurveyor capitalRegistration statement

CG Oncology Raises $105M for Bladder Cancer Work - Orange County Business Journal

CG Oncology Inc., an Irvine-based cancer research firm that says it’s making “significant clinical progress” on bladder cancer treatments, this month announced the close of an oversubscribed $105 million crossover financing round.

United statesAndrea maddox smithArthur kuanGiuliano marosticaJohns hopkins universityMalin corporationAvanir pharmaceuticalsNational cancer instituteBladder cancer advocacy networkSpectrum centerCg oncology incForesite capitalOrange countyNational cancerSan francisco based foresite capitalAvidity partners